Related Experiment Video
Updated: Jun 10, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Global research trends of lean metabolic dysfunction-associated steatotic liver disease (lean MASLD) from 2005 to
1Department of Gastroenterology, Wuxi Xinwu District Xinrui Hospital, Wuxi, Jiangsu Province, China.
Background:
To analyze the research status, hotspots, and frontiers of lean metabolic dysfunction-associated steatotic liver disease (lean MASLD) in the past 20 years using bibliometrics, providing references for further related research.
Methods:
Literature on lean MASLD was retrieved from the Web of Science Core Collection database. Visual analyses of publication trends, author distribution, research institutions, journal distribution, cited documents, and keywords, were performed using VOSviewer, the "Bibliographic" package in R, and CiteSpace software.
Results:
A total of 2008 documents were included. The publication output on lean MASLD increased annually and peaked in 2023. This literature originated from 82 countries/regions, with the United States contributing the most publications. Harvard University was the institution with the highest publication count, PLOS ONE was the top journal in this field, and Prof Wong, Vincent Wai-Sun from The Chinese University of Hong Kong was the most productive author. The research on lean MASLD at that time primarily focused on etiology and treatment (e.g., hepatic steatosis, insulin resistance, metabolic syndrome, oxidative stress, inflammation, abdominal obesity, sarcopenia, patatin-like phospholipase domain-containing 3 gene, and gut microbiota), as well as epidemiology and diagnostic methods.
Conclusion:
This study systematically depicted the 2-decade developmental trajectory of lean MASLD using bibliometric methods for the first time, and provides academic references for clinicians and scholars to grasp the field's hotspots, frontiers, and evolutionary trends.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

